Project Search Results

Select

Research Categorization

Operator
Operator

Project Details

Operator
Operator

Contact Researcher and Awardee Organization

Operator
Operator

Funding Organization

Operator
Operator
Operator
Operator
Displaying 11 - 20 of 1116 Clinical Trials
ID/Name Source Type
24-week Open-label Extension Study Evaluating PXT00864 Effect in Mild AD Patients Further to PLEODIAL-I Completion
NCT02361242 clinicaltrials.gov Clinical Trial
3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease
NCT01374438 clinicaltrials.gov Clinical Trial
4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease
NCT01039701 clinicaltrials.gov Clinical Trial
A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted Tauopathies
NCT01056965 clinicaltrials.gov Clinical Trial
A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease
NCT01047579 clinicaltrials.gov Clinical Trial
A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)
NCT00622713 clinicaltrials.gov Clinical Trial
A 24-month Randomised Parallel Group Single-blinded Multi-centre Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia
NCT03174886 clinicaltrials.gov Clinical Trial
A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease
NCT02956486 clinicaltrials.gov Clinical Trial
A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease_
NCT03036280 clinicaltrials.gov Clinical Trial
A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease
NCT01399125 clinicaltrials.gov Clinical Trial